Filgotinib for treating Ulcerative Colitis - share your experience

To help write our consultation response, which will set out our views, we want to hear from people with Ulcerative Colitis who have been treated with filgotinib.

We want to know what effect the medicine had on your symptoms and how you live your life, as well as how filgotinib compares to other medicines you have taken for your Ulcerative Colitis. We would also like to hear from people for whom all medicines so far have not worked or are no longer working. How does this impact on your day-to-day life and what alternatives have you been offered?

Filgotinib is part of the class of drugs called Janus kinase (JAK) inhibitors, which are currently used to treat arthritis. JAKs are enzymes that play a role in activating the body's immune response.

In the UK, before a medicine or technology (e.g. diagnostic test or device) can be recommended for routine use by the NHS, it is assessed for its clinical and cost effectiveness. The UK organisations responsible for this include the National Institute of Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC) and All Wales Medicine Strategy Group (AWMSG). We ask for your views because these are important in providing unique knowledge about what it's like to live with a condition. They can make a huge difference to the final decisions about whether this drug should be widely available for people across the UK.

CONTACT US

Please share your experiences by emailing policy@crohnsandcolitis.org.uk before Thursday 1st April 2021. If you would be interested in sharing your experience in person with the NICE Committee (via Zoom), please make a note of this in your email and we will get back in contact with you. This has now closed.

We may use anonymous quotes to help bring our submission to NICE to life but will not share personal details. We might also use the views you share to inform our submissions to other bodies that make decisions about the availability of medicines in other parts of the UK, such as the Scottish Medicines Consortium or All Wales Medicines Strategy Group.

Find out about biologics, biosmilars and other drug treatments.

Read how we remove barriers that prevent patients accessing the most effective treatments.

For more information about this consultation visit the NICE website.